Citalopram for Agitation in Alzheimer's Disease

Summary

The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.

Conditions

• Alzheimer's Disease
• Agitation

Interventions

DRUG

citalopram

target dose 30mg daily for 9 weeks

DRUG

placebo

daily for 9 weeks

Sponsors & Collaborators

• National Institute on Aging (NIA)

  collaborator NIH

• National Institute of Mental Health (NIMH)

  collaborator NIH

• JHSPH Center for Clinical Trials

  lead OTHER

Principal Investigators

• Constantine Lyketsos, MD, MHS · Johns Hopkins University

• Lon Schneider, MD · University of Southern California Keck School of Medicine Memory and Aging Center

• Bruce Pollock, MD · Centre for Addiction and Mental Health

• Jacobo Mintzer, MD · Medical University of South Carolina Alzheimer's Research and Clinical Programs

• David Shade, Esq · Johns Hopkins University

• Davengere Devanand, MD · Columbia University

• Paul Rosenberg, MD · Johns Hopkins University

• Daniel Weintraub, MD · University of Pennsylvania

• Anton Porsteinsson, MD · University of Rochester

• Jerome Yesavage, MD · Stanford University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2009-07-31

Primary Completion

2013-09-30

Completion

2013-09-30

Countries

• United States
• Canada

Study Locations